Big picture - Why invest in Silence Therapeutics plc
Silence Therapeutics plc Snapshot
Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value.
Silence’s strategy is based on translating our intellectual property, our siRNA technology and delivery systems, into successful commercial drug products. We have the expertise and the patented technology required to develop siRNA based drug candidates internally as well as to establish fruitful collaborations with suitable partners.
Ensuring appropriate target gene selection and maintaining a diversified pre-clinical engine are key aspects of our strategic approach. We aim to evaluate as many potential applications of our technology as possible in the early, more affordable phases of our candidate-generating pipeline in order to better manage risk and the costs of failure.
Our strategy plays to the strengths of our platform technology, which include:
Our siRNA molecules are designed to target a single mRNA in the cell, only affecting the expression of the disease-causing gene. Our delivery systems ensure further specificity by delivering therapeutic siRNA only to one target cells in the body.
Our technology consists of two components: siRNA plus delivery system.
By engineering the siRNA molecule, a different gene can be targeted to tackle a new disease. This modular nature is the basis of our versatile platform technology.
Well understood mode of action
RNA interference is a well characterised natural pathway, which leads to the degradation of target mRNA. The precision of the RNA interference process translates in better predictability of the biological effects of siRNA based drugs.
Accelerated discovery timelines
Knowing the sequence of the human genome means that potent therapeutic siRNA molecules can be identified quickly, ready to be tested in the relevant models.
FOR FURTHER INFORMATION PLEASE CLICK HERE
Our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease-causing genes, allowing cells to revert to their healthy state. We achieve this through harnessing the endogenous pathway of RNA interference (RNAi), which was a breakthrough discovery in the field of molecular biology that was first described in the late 1990s and later recognised with a Nobel prize in 2006.
Given the tailored inhibition of selected genes and the added precision brought by targeted delivery systems, RNAi-based therapies are thought to carry lower risk of failure than traditional approaches as the biological effects are more predictable. We are working to maximise the therapeutic applications of our versatile toolkit.
Email - [email protected]
Corporate Headquarters - UK Germany
72 Hammersmith Road,
t +44 (0)20 3457 6900
Nominated adviser and broker
Peel Hunt LLP
120 London Wall
Covington & Burling LLP
Capital IRG plc